Integra LifeSciences Holdings (IART) 2017年年度报告「NASDAQ」.pdf

1、Driving Growth2017 Annual ReportTO OUR SHAREHOLDERSIn 2017,we made Integra LifeSciences an even stronger company.We completed two transformative acquisitions to solidify our global leadership position in neurosurgery and regenerative technologies.We launched a number of new products,made significant

2、 investments in our R&D capabilities,improved our supply chain management and maintained our focus on operational excellence.We invested in our sales channels to create specialization and achieve greater focus in addressing our customers needs.By year-end,we passed the$1 billion revenue milestone.Th

3、ese accomplishments strengthened our market position in key segments and enabled us to continue to deliver value to our shareholders.In 2017,we finished the year financially strong,with increased organic growth from our base business and solid performance from our recently acquired businesses.Total

4、revenues for 2017 were$1.19 billion,an increase of$196.2 million,or 19.8 percent,over the prior year.The Codman Specialty Surgical segment,which contributed 61 percent of our revenues,grew 13.9 percent to$720.3 million versus the prior year.We attribute this growth to revenue contributions from the

5、Codman Neurosurgery acquisition,the global launch of CUSA Clarity ultrasonic tissue ablation system,and growth in our dural access and repair franchise.The Orthopedics and Tissue Technologies segment grew 30.1 percent to$467.9 million versus a year ago,primarily driven by revenue contributions from

6、the Derma Sciences acquisition,strong performance in our regenerative technologies franchise including our private-label business and growth in our ankle and shoulder product portfolios.These encouraging results demonstrate we can achieve our goals by executing on clear strategies,capitalizing on ou